'One-visit' therapy for pelvic inflammatory disease

Area of Science:

• Gynecology
• Infectious Diseases
• Pharmacology

Background:

• Acute pelvic inflammatory disease (PID) is a common gynecological disorder.
• Often caused by mixed aerobic and anaerobic infections, making routine bacteriological investigation challenging.
• Current therapeutic approaches may face challenges with patient compliance, especially in outpatient settings.

Purpose of the Study:

• To compare the therapeutic efficacy of two different treatment regimens for acute PID.
• To evaluate the convenience and compliance benefits of a once-only administration regimen.
• To assess the effectiveness of ornidazole and sulphadoxine compared to metronidazole and sulphadimidine in PID treatment.

Main Methods:

• An open comparative trial involving 60 patients with acute PID.
• Patients were divided into two groups of 30.
• Both groups received a combination of penicillins, probenecid, a sulphonamide, and an imidazole derivative, with variations in the specific drugs used (ornidazole/sulphadoxine vs. metronidazole/sulphadimidine).

Main Results:

• Both treatment regimens demonstrated virtually the same therapeutic response in hospitalized patients.
• The regimen including ornidazole and the ultralong-acting sulphonamide, sulphadoxine, allowed for a once-only administration.
• This once-only administration significantly reduces the potential for non-compliance in patients, particularly those treated on an outpatient basis.

Conclusions:

• A once-only administration regimen of ornidazole and sulphadoxine is as effective as other combination therapies for acute PID.
• This simplified dosing regimen offers a significant advantage in improving patient compliance for PID treatment.
• The findings support the use of ornidazole and sulphadoxine for a more convenient and potentially more effective outpatient management of acute pelvic inflammatory disease.